Biopharmaceuticals
Follow Biopharmaceuticals on Notably News to receive short updates to your email — rarely!
We include updates on AbbVie, Amgen, Cipla, Gene therapy, Lactase, Stem-cell therapy, Gilead Sciences, Biopharmaceutical, Recombinant DNA, Serum Institute of India, Vertex Pharmaceuticals, Onasemnogene abeparvovec, Samsung Biologics, BeiGene, CSL Behring, Jazz Pharmaceuticals ... and more.
| January 2025 | Vertex Pharmaceuticals gained FDA approval for Journavx (suzetrigine), a groundbreaking non-opioid treatment for moderate to severe acute pain, marking the first new type of pain medicine approved in 25 years. |
| 2024 | Vertex achieved broad availability of CF medications in over 60 countries, with approximately two-thirds of diagnosed patients receiving treatment worldwide. |
| December 2024 | AbbVie acquired Nimble Therapeutics, a Roche spinout developing oral peptide treatments in autoimmune areas, for $200 million. |
| October 2024 | AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline. |
| June 2024 | NICE and Vertex reached an agreement on acceptable pricing terms, extending the 2019 pricing deal to include Vertex's cystic fibrosis drugs and ensuring patient access to future license extensions. |
| June 1 2024 | Robert Michael replaced Richard Gonzalez as CEO of AbbVie, with Gonzalez becoming executive chairman. |
| April 2024 | Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore. |
| April 2024 | Vertex agreed to acquire Alpine Immune Sciences, a Seattle-based clinical stage biopharmaceutical company, for $4.9 billion. |
| March 2024 | AbbVie announced the acquisition of Landos Biopharma for over $200 million. |
| January 2024 | Samina Hamied resigned from her position as Executive Vice Chairperson of Cipla, while continuing to serve as a non-executive director subject to rotational retirement. |
| 2023 |
Stem-cell therapy
A case was published of a woman who developed Mycobacterium abscessus infection and meningitis after receiving stem cell treatment for multiple sclerosis at a commercial clinic in Baja California, Mexico.
|
| 2023 | CureVac adjusted its goal for obtaining official approval for the marketability of an improved Covid-19 vaccine, now projected for 2023 at the earliest. |
| 2023 | Vertex secured reimbursement agreements for CF medicines in 36 countries, with 35 being high-income nations. At this time, approximately 51,322 CF patients were treated with Trikafta, with patient distribution at 49% in the U.S., 42% in Europe, and 9% in Canada, Israel, Australia, and New Zealand. |
| 2023 | Humira began facing competition from Amgen's biosimilar, potentially impacting its market dominance after years of being the company's primary revenue generator. |
| December 2023 | AbbVie announced the acquisition of neuroscience drugmaker Cerevel Therapeutics for $8.7 billion to expand its drug pipeline, completed in August 2024. |
| November 2023 | AbbVie announced the acquisition of ImmunoGen for $10.1 billion to expedite its entry into the ovarian cancer treatment market, with the deal finalized in February 2024. |
| October 2023 | NICE initially declined to recommend Vertex's cystic fibrosis drugs Kaftrio, Symkevi, and Orkambi due to high costs beyond acceptable NHS resource limits. |
| October 8 2023 | The R21/Matrix-M malaria vaccine received a recommendation for use by the WHO's Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). |
| September 2023 | Cipla South Africa announced the acquisition of Actor Pharma, a Midrand-headquartered healthcare products manufacturer. |
| June 2023 |
Delandistrogene moxeparvovec
Delandistrogene moxeparvovec (brand name Elevidys) received medical approval in the United States as a gene therapy treatment for Duchenne muscular dystrophy.
|
| 2022 | CureVac determined that an approval-relevant study for the new vaccine could only be carried out in the fourth quarter of 2022. |
| 2022 | Cipla reported having over 25,000 employees in their annual report, with women comprising 14.3% of the workforce. |
| 2022 | Imbruvica was priced at $181,529 annually, with patients taking four pills daily facing a cost of $242,039. |
| July 2022 | Vertex announced the acquisition of ViaCyte, Inc. for $320 million. |
| July 2022 | AbbVie agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid painkillers. The company denied any wrongdoing, and its stock fell 6 percent following an earnings report that included a $2.2 billion charge related to the opioid settlement. |
| March 2022 | AbbVie acquired Syndesi Therapeutics for up to $1 billion, including its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. |
| January 2022 | The start of the phase 1 study with the product candidate CV2CoV was postponed from the fourth quarter of 2021 to the first quarter of 2022. |
| 2021 |
Stem-cell therapy
Stem cell injections in the US caused severe infections in at least 20 patients who received umbilical cord blood-derived products marketed as 'stem cell treatment'.
|
| October 2021 | The company decided to abandon further research and development of CVnCoV and announced a collaboration with GSK to develop improved mRNA vaccine technology. |
| July 13 2021 | RDIF announced that Serum Institute of India would start production of Sputnik V vaccine doses in September 2021, with plans to produce over 300 million doses annually in India. |
| June 2021 |
Teserpaturev
Japanese Ministry of Health, Labour and Welfare (MHLW) approved teserpaturev (Delytact) as the first gene therapy product for malignant glioma treatment.
|
| June 2021 | The United States Senate Finance Committee, led by Chair Ron Wyden, initiated an investigation into AbbVie's potential tax avoidance strategies, focusing on the company's stock buybacks and international profit shifting following the 2017 Tax Cuts and Jobs Act. |
| June 2021 | AbbVie acquired TeneoOne and its lead compound TNB-383B, a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. |
| June 16 2021 | CureVac announced results of Phase III trials showing its mRNA vaccine had an efficacy of 47%, which fell short of the European Medicines Agency's target of at least 50%. |
| March 2021 | An agreement was reached to supply Covishield vaccine doses to the UK. |
| March 2021 | Reuters reported that the Chinese state-backed cyber-espionage group Red Apollo targeted Serum Institute of India's intellectual property for exfiltration. |
| February 12 2021 | CureVac initiated a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, starting a time-optimized review process for potential market authorization. |
| January 2021 |
Stem-cell therapy
The FDA approved the first clinical trial for an investigational stem cell therapy aimed at restoring lost brain cells in people with advanced Parkinson's disease.
|
| January 2021 | CureVac announced a clinical development collaboration with Bayer for its COVID-19 vaccine CVnCoV (active ingredient zorecimeran). |
| 2020 |
Stem-cell therapy
The FDA and FTC took action by sending warning letters to stem cell firms making misleading COVID-19-related marketing claims.
|
| 2020 |
Stem-cell therapy
Some stem cell clinics began marketing unproven and non-FDA-approved stem cells and exosomes for COVID-19 treatment, despite NIH recommendations against such use.
|
| 2020 |
Stem-cell therapy
A phase 2 clinical trial found significantly improved outcomes for patients with multiple sclerosis who were treated with mesenchymal stem cells compared to those receiving a sham treatment.
|
| 2020 | AbbVie agreed to pay $24 million to resolve allegations of kickback schemes promoting its rheumatoid arthritis drug Humira using 'nurse ambassadors'. |
| 2020 | AbbVie reported a pretax loss of $4.5 billion in the United States, contrasted with an overseas pretax profit of $7.9 billion, which prompted scrutiny from Senator Ron Wyden regarding potential tax avoidance practices. |
| 2020 | AbbVie's global sales of ibrutinib increased to $5 billion. |
| December 2020 | Serum Institute of India sought emergency approval for the Covishield vaccine developed with AstraZeneca. |
| December 2020 | CureVac began a Phase III clinical trial of CVnCoV COVID-19 vaccine with 36,500 participants, with Bayer providing clinical trial support and international logistics. |
| December 31 2020 | AbbVie reported total CO2e emissions (Direct + Indirect) of 508 kilotonnes, representing a 10.1% year-over-year reduction from the previous year. |
| September 2020 | COVID-19 vaccine trials for AZD1222 (Covishield) were temporarily halted by DCGI after a volunteer in Oxford developed an illness following vaccination, but were soon resumed after British regulators' consent. |
| August 2020 | Elon Musk reviewed the Tesla-CureVac project while in Germany, and the companies filed a joint patent on the RNA microfactory technology. |
|
We are only showing the most recent entries for this topic. |
|
This contents of the box above is based on material from the Wikipedia articles Serum Institute of India, Delandistrogene moxeparvovec, Cipla, AbbVie, Teserpaturev, Vertex Pharmaceuticals, Stem-cell therapy & CureVac, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.